Loading clinical trials...
Loading clinical trials...
A Multicenter, Parallel-group, Rater-blinded, Randomized Clinical Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of 2 Dosing Regimens of ND0612H [ ] in Subjects With Advanced Parkinson's Disease
Conditions
Interventions
ND0612 (Levodopa/Carbidopa solution)
ND0612 (Levodopa/Carbidopa solution) + morning oral IR-LD/CD
Locations
11
United States
Northwestern University
Chicago, Illinois, United States
QUEST Research Institute
Farmington Hills, Michigan, United States
University of Cincinnati
Cincinnati, Ohio, United States
Medical University Innsbruck
Innsbruck, Austria
Rabin Medical Center
Petah Tikva, Israel
Chaim Sheba Medical Center
Ramat Gan, Israel
Start Date
December 29, 2015
Primary Completion Date
December 20, 2016
Completion Date
January 31, 2017
Last Updated
May 25, 2023
NCT07330258
NCT06508801
NCT07384429
NCT07310264
NCT02119611
NCT07216976
Lead Sponsor
NeuroDerm Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions